Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy
Purpose Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (50 Gy) with or without chemotherapy. Methods One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherap...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2017-05, Vol.25 (5), p.1439-1443 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1443 |
|---|---|
| container_issue | 5 |
| container_start_page | 1439 |
| container_title | Supportive care in cancer |
| container_volume | 25 |
| creator | Rastogi, Madhup Khurana, Rohini Revannasiddaiah, Swaroop Jaiswal, Isha Nanda, Sambit S Gupta, Pooja Chufal, Kundan S Bhatt, M L |
| description | Purpose
Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (50 Gy) with or without chemotherapy.
Methods
One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly.
Results
Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (
p
= 0.038) and 51.7 vs. 27.3% (
p
= 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (
p
= 0.18), 27.6 vs. 9.1% (
p
= 0.06), and 6.9 vs. 0% (
p
= 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (
p
= 0.091) and 53.6% vs. 43.3% (
p
= 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but
p
> 0.05.
Conclusion
Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated. |
| doi_str_mv | 10.1007/s00520-016-3548-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852692542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A550952132</galeid><sourcerecordid>A550952132</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-8e1debb0ff87be1db059d3cb09f5147b5a01b7ff6e28bab6fc135994599dc63b3</originalsourceid><addsrcrecordid>eNp1kt1qFTEUhQdR7LH6AN5IwJt6MTWZTGYmN0IpWoWCIHod8rPTSZ1JjklGOT5N7_oePpkZT-sfSgg7ZH9rsUNWVT0m-Jhg3D9PGLMG15h0NWXtUPM71Ya0lNY9pfxutcG8JXVLGTuoHqR0iTHpe9bcrw6ang996W6q63dhAhQsUuC_7oycnQc07kwMepxCdAaQ8yiPgLYRPoPPLvgVD1FOaF50SC67tDIjSIOkN8iD_oi09Boi2srsiiihHEFmMOiLyyOK0rhQPKPc7tDRC4a_XZ3tnu17If6oYclIjzDfYg-re1ZOCR7d1MPqw6uX709f1-dvz96cnpzXuu1YrgcgBpTC1g69KmeFGTdUK8wtI22vmMRE9dZ20AxKqs5qQhnnbdlGd1TRw-po77uN4dMCKYvZJQ3TJD2EJQkysKbjDWubgj79C70MS_RlukINtO3b8jG_qAs5gXDehhylXk3FCWOYs4bQ1ev4H1RZBmangwfryv0fArIX6BhSimDFNrpZxp0gWKzhEPtwiDKDWMMheNE8uRl4UTOYn4rbNBSg2QOptPwFxN9e9F_X78NhxtY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1883474016</pqid></control><display><type>article</type><title>Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rastogi, Madhup ; Khurana, Rohini ; Revannasiddaiah, Swaroop ; Jaiswal, Isha ; Nanda, Sambit S ; Gupta, Pooja ; Chufal, Kundan S ; Bhatt, M L</creator><creatorcontrib>Rastogi, Madhup ; Khurana, Rohini ; Revannasiddaiah, Swaroop ; Jaiswal, Isha ; Nanda, Sambit S ; Gupta, Pooja ; Chufal, Kundan S ; Bhatt, M L</creatorcontrib><description>Purpose
Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy.
Methods
One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly.
Results
Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (
p
= 0.038) and 51.7 vs. 27.3% (
p
= 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (
p
= 0.18), 27.6 vs. 9.1% (
p
= 0.06), and 6.9 vs. 0% (
p
= 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (
p
= 0.091) and 53.6% vs. 43.3% (
p
= 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but
p
> 0.05.
Conclusion
Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-016-3548-9</identifier><identifier>PMID: 27987094</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Benzydamine - therapeutic use ; Cancer patients ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - radiotherapy ; Care and treatment ; Chemoradiotherapy - adverse effects ; Chemotherapy ; Disease prevention ; Dose-Response Relationship, Radiation ; Female ; Head & neck cancer ; Head and neck cancer ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - radiotherapy ; Humans ; Inflammation ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mouthwashes - therapeutic use ; Nursing ; Nursing Research ; Oncology ; Original Article ; Pain Medicine ; Prospective Studies ; Radiation (Physics) ; Radiation Injuries - etiology ; Radiation Injuries - prevention & control ; Radiation therapy ; Rehabilitation Medicine ; Side effects ; Squamous Cell Carcinoma of Head and Neck ; Stomatitis ; Stomatitis - etiology ; Stomatitis - prevention & control ; Young Adult</subject><ispartof>Supportive care in cancer, 2017-05, Vol.25 (5), p.1439-1443</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><rights>COPYRIGHT 2017 Springer</rights><rights>Supportive Care in Cancer is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-8e1debb0ff87be1db059d3cb09f5147b5a01b7ff6e28bab6fc135994599dc63b3</citedby><cites>FETCH-LOGICAL-c465t-8e1debb0ff87be1db059d3cb09f5147b5a01b7ff6e28bab6fc135994599dc63b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-016-3548-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-016-3548-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27987094$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rastogi, Madhup</creatorcontrib><creatorcontrib>Khurana, Rohini</creatorcontrib><creatorcontrib>Revannasiddaiah, Swaroop</creatorcontrib><creatorcontrib>Jaiswal, Isha</creatorcontrib><creatorcontrib>Nanda, Sambit S</creatorcontrib><creatorcontrib>Gupta, Pooja</creatorcontrib><creatorcontrib>Chufal, Kundan S</creatorcontrib><creatorcontrib>Bhatt, M L</creatorcontrib><title>Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy.
Methods
One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly.
Results
Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (
p
= 0.038) and 51.7 vs. 27.3% (
p
= 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (
p
= 0.18), 27.6 vs. 9.1% (
p
= 0.06), and 6.9 vs. 0% (
p
= 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (
p
= 0.091) and 53.6% vs. 43.3% (
p
= 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but
p
> 0.05.
Conclusion
Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Benzydamine - therapeutic use</subject><subject>Cancer patients</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Care and treatment</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Chemotherapy</subject><subject>Disease prevention</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Female</subject><subject>Head & neck cancer</subject><subject>Head and neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mouthwashes - therapeutic use</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Prospective Studies</subject><subject>Radiation (Physics)</subject><subject>Radiation Injuries - etiology</subject><subject>Radiation Injuries - prevention & control</subject><subject>Radiation therapy</subject><subject>Rehabilitation Medicine</subject><subject>Side effects</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><subject>Stomatitis</subject><subject>Stomatitis - etiology</subject><subject>Stomatitis - prevention & control</subject><subject>Young Adult</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kt1qFTEUhQdR7LH6AN5IwJt6MTWZTGYmN0IpWoWCIHod8rPTSZ1JjklGOT5N7_oePpkZT-sfSgg7ZH9rsUNWVT0m-Jhg3D9PGLMG15h0NWXtUPM71Ya0lNY9pfxutcG8JXVLGTuoHqR0iTHpe9bcrw6ang996W6q63dhAhQsUuC_7oycnQc07kwMepxCdAaQ8yiPgLYRPoPPLvgVD1FOaF50SC67tDIjSIOkN8iD_oi09Boi2srsiiihHEFmMOiLyyOK0rhQPKPc7tDRC4a_XZ3tnu17If6oYclIjzDfYg-re1ZOCR7d1MPqw6uX709f1-dvz96cnpzXuu1YrgcgBpTC1g69KmeFGTdUK8wtI22vmMRE9dZ20AxKqs5qQhnnbdlGd1TRw-po77uN4dMCKYvZJQ3TJD2EJQkysKbjDWubgj79C70MS_RlukINtO3b8jG_qAs5gXDehhylXk3FCWOYs4bQ1ev4H1RZBmangwfryv0fArIX6BhSimDFNrpZxp0gWKzhEPtwiDKDWMMheNE8uRl4UTOYn4rbNBSg2QOptPwFxN9e9F_X78NhxtY</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Rastogi, Madhup</creator><creator>Khurana, Rohini</creator><creator>Revannasiddaiah, Swaroop</creator><creator>Jaiswal, Isha</creator><creator>Nanda, Sambit S</creator><creator>Gupta, Pooja</creator><creator>Chufal, Kundan S</creator><creator>Bhatt, M L</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy</title><author>Rastogi, Madhup ; Khurana, Rohini ; Revannasiddaiah, Swaroop ; Jaiswal, Isha ; Nanda, Sambit S ; Gupta, Pooja ; Chufal, Kundan S ; Bhatt, M L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-8e1debb0ff87be1db059d3cb09f5147b5a01b7ff6e28bab6fc135994599dc63b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Benzydamine - therapeutic use</topic><topic>Cancer patients</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Care and treatment</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Chemotherapy</topic><topic>Disease prevention</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Female</topic><topic>Head & neck cancer</topic><topic>Head and neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mouthwashes - therapeutic use</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Prospective Studies</topic><topic>Radiation (Physics)</topic><topic>Radiation Injuries - etiology</topic><topic>Radiation Injuries - prevention & control</topic><topic>Radiation therapy</topic><topic>Rehabilitation Medicine</topic><topic>Side effects</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><topic>Stomatitis</topic><topic>Stomatitis - etiology</topic><topic>Stomatitis - prevention & control</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rastogi, Madhup</creatorcontrib><creatorcontrib>Khurana, Rohini</creatorcontrib><creatorcontrib>Revannasiddaiah, Swaroop</creatorcontrib><creatorcontrib>Jaiswal, Isha</creatorcontrib><creatorcontrib>Nanda, Sambit S</creatorcontrib><creatorcontrib>Gupta, Pooja</creatorcontrib><creatorcontrib>Chufal, Kundan S</creatorcontrib><creatorcontrib>Bhatt, M L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rastogi, Madhup</au><au>Khurana, Rohini</au><au>Revannasiddaiah, Swaroop</au><au>Jaiswal, Isha</au><au>Nanda, Sambit S</au><au>Gupta, Pooja</au><au>Chufal, Kundan S</au><au>Bhatt, M L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>25</volume><issue>5</issue><spage>1439</spage><epage>1443</epage><pages>1439-1443</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy.
Methods
One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly.
Results
Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (
p
= 0.038) and 51.7 vs. 27.3% (
p
= 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (
p
= 0.18), 27.6 vs. 9.1% (
p
= 0.06), and 6.9 vs. 0% (
p
= 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (
p
= 0.091) and 53.6% vs. 43.3% (
p
= 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but
p
> 0.05.
Conclusion
Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27987094</pmid><doi>10.1007/s00520-016-3548-9</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2017-05, Vol.25 (5), p.1439-1443 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1852692542 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Benzydamine - therapeutic use Cancer patients Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Care and treatment Chemoradiotherapy - adverse effects Chemotherapy Disease prevention Dose-Response Relationship, Radiation Female Head & neck cancer Head and neck cancer Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - radiotherapy Humans Inflammation Male Medicine Medicine & Public Health Middle Aged Mouthwashes - therapeutic use Nursing Nursing Research Oncology Original Article Pain Medicine Prospective Studies Radiation (Physics) Radiation Injuries - etiology Radiation Injuries - prevention & control Radiation therapy Rehabilitation Medicine Side effects Squamous Cell Carcinoma of Head and Neck Stomatitis Stomatitis - etiology Stomatitis - prevention & control Young Adult |
| title | Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A05%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20benzydamine%20hydrochloride%20in%20the%20prevention%20of%20oral%20mucositis%20in%20head%20and%20neck%20cancer%20patients%20treated%20with%20radiotherapy%20(%3E50%C2%A0Gy)%20with%20or%20without%20chemotherapy&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Rastogi,%20Madhup&rft.date=2017-05-01&rft.volume=25&rft.issue=5&rft.spage=1439&rft.epage=1443&rft.pages=1439-1443&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-016-3548-9&rft_dat=%3Cgale_proqu%3EA550952132%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1883474016&rft_id=info:pmid/27987094&rft_galeid=A550952132&rfr_iscdi=true |